Engineered Albumin Extends Protein Drug Lifespan and Enables Mucosal Delivery

Protein-based medicines have revolutionized treatment for many diseases, but a major drawback persists: they are typically cleared rapidly from the bloodstream, necessitating frequent injections that burden patients. Now, researchers have engineered albumin—a natural blood protein—to help therapeutic proteins last longer in circulation and cross mucosal barriers, potentially enabling non-injected delivery. The innovation could transform care for patients requiring long-term or lifelong treatment, reducing injection frequency and improving quality of life. While the source does not specify exact numbers or company names, the advance addresses a critical unmet need in drug delivery. By leveraging albumin's natural longevity and transport properties, this approach may open doors to oral, nasal, or pulmonary administration of biologics. If successfully translated, it could lower healthcare costs and expand access to vital therapies. The work underscores a broader trend toward patient-friendly drug formulations. Next steps likely include preclinical testing to validate efficacy and safety across different protein drugs and mucosal routes.